AGI-5198 - CAS 1355326-35-0
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
AGI-5198
Catalog Number:
1355326-35-0
Synonyms:
IDH-C35
CAS Number:
1355326-35-0
Description:
AGI-5198 is the first highly potent and selective inhibitor of IDH1 R132H/R132C mutants with IC50 of 0.07 μM/0.16 μM.
Molecular Weight:
462.56
Molecular Formula:
C27H31FN4O2
COA:
Inquire
MSDS:
Inquire
Targets:
Isocitrate Dehydrogenase (IDH)
Chemical Structure
CAS 1355326-35-0 AGI-5198

Related Isocitrate Dehydrogenase (IDH) Products


GSK321
(CAS: 1816331-63-1)

GSK321 is a highly potent, selective inhibitor of mutant IDH1 enzymes, with IC50= 4.6 nM against R132H, 3.8 nM against R132C and 2.9 nM against R132G. GSK321 st...

Mutant IDH1-IN-1
(CAS: 1355326-21-4)

Mutant IDH1-IN-1, a mutant IDH1 R132H inhibitor, could be used in some biological studies.

CAS 1432660-47-3 AGI-6780

AGI-6780
(CAS: 1432660-47-3)

CAS 1355326-35-0 AGI-5198

AGI-5198
(CAS: 1355326-35-0)

AGI-5198 is the first highly potent and selective inhibitor of IDH1 R132H/R132C mutants with IC50 of 0.07 μM/0.16 μM.

Enasidenib (AG-221)
(CAS: 1446502-11-9)

Enasidenib, aslo known as AG-221 and CC-90007, is a potent and selective IDH2 inhibitor with potential anticancer activity (IDH2 = Isocitrate dehydrogenase 2).

Mutant IDH1-IN-2
(CAS: 1429176-69-1)

Mutant IDH1-IN-2, aslo called as SCHEMBL14831158, is an inhibitor of mutant IDH protein. It is developed for the treatment of diseases associated with such muta...

SCHEMBL14831541
(CAS: 1429180-08-4)

SCHEMBL14831541, also called as Mutant IDH1 inhibitor, is an inhibitor of mutant IDH1 which is key enzymes found in cellular metabolism.

Ivosidenib
(CAS: 1448347-49-6)

Ivosidenib, also called AG-120, is an oral inhibitor that specifically inhibits a mutated form of IDH1 in the cytoplasm.

Reference Reading


1.Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198.
Molenaar RJ1, Botman D2, Smits MA2, Hira VV2, van Lith SA3, Stap J2, Henneman P4, Khurshed M2, Lenting K3, Mul AN4, Dimitrakopoulou D2, van Drunen CM5, Hoebe RA2, Radivoyevitch T6, Wilmink JW7, Maciejewski JP8, Vandertop WP9, Leenders WP3, Bleeker FE4, va Cancer Res. 2015 Nov 15;75(22):4790-802. doi: 10.1158/0008-5472.CAN-14-3603. Epub 2015 Sep 11.
Isocitrate dehydrogenase 1 (IDH1) is mutated in various types of human cancer to IDH1(R132H), a structural alteration that leads to catalysis of α-ketoglutarate to the oncometabolite D-2-hydroxyglutarate. In this study, we present evidence that small-molecule inhibitors of IDH1(R132H) that are being developed for cancer therapy may pose risks with coadministration of radiotherapy. Cancer cells heterozygous for the IDH1(R132H) mutation exhibited less IDH-mediated production of NADPH, such that after exposure to ionizing radiation (IR), there were higher levels of reactive oxygen species, DNA double-strand breaks, and cell death compared with IDH1 wild-type cells. These effects were reversed by the IDH1(R132H) inhibitor AGI-5198. Exposure of IDH1 wild-type cells to D-2-hydroxyglutarate was sufficient to reduce IDH-mediated NADPH production and increase IR sensitivity. Mechanistic investigations revealed that the radiosensitivity of heterozygous cells was independent of the well-described DNA hypermethylation phenotype in IDH1-mutated cancers.